Inactive Instrument

Other languages Amarillo Biosciences, Inc. Other OTC

Equities

AMAR

US02301P2056

Other languages

Unlock all the news on all businesses: Never miss an investment opportunity again!

Ainos to Start Clinical Trial of Potential Animal Drug for Oral Disease Treatment	05-15
Ainos, Inc. to Initiate Clinical Study of New Potential VELDONA-Based Animal Drug, Expanding VELDONA's Potential Market	05-15
Ainos, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024	05-13
Traders Anticipate Inflation Report as US Equities Open Lower on Wall Street	03-11
Top Premarket Decliners	03-11
Ainos, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023	03-08
Top Premarket Gainers	03-08
Ainos, Inc. Submits Clinical Hold Complete Response to US FDA to Resolve the Deficiencies on Investigational New Drug Phase Ii Trial of Its Veldona Formulation Against Mild Covid-19 Symptoms	02-05
Ainos, Inc. Enters into Five-Year Product Development Agreement with Taiwan Carbon Nano Technology Corporation	01-12
Wall Street Set to Open Lower as Monthly Jobs Data Much Stronger Than Expected	01-05
Ainos Regains Compliance With Nasdaq Listing Rule	01-02
Ainos, Nisshinbo Micro Devices and Inabata Initiate Phase 2 of VOC Co-Development Powered by Ai Nose, Accelerating the Digitalization of Smell	12-26
Ainos, Inc. Announces Resignation of John Junyong Lee as Chief Legal Counsel and Corporate Secretary	12-22
Ainos Says Three Clinical Studies for Veldona Show 'Positive' Data	11-21
Ainos, Inc. Announces Positive Data Reports from its Clinical Studies for VELDONA as Potential Treatment of Oral Warts in HIV-Seropositive Patients, an Orphan Drug Designated by the FDA	11-21
Ainos, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023	11-09
Ainos, Inc. Signs MoU for Contract Clinical Trials to Conduct Clinical Study of Potential New Animal Drug Based on Veldona	11-06
Ainos Says Candidate Treatment for HIV Oral Warts Gets Orphan Drug Designation	18/09/23
Ainos, Inc. Commences Shipping its VELDONA Pet Cytoprotein Supplements in Taiwan	05/09/23
Ainos, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2023	11/08/23

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Other languages Amarillo Biosciences, Inc. Other OTC

Equities

AMAR

US02301P2056

Other languages

Filters